分子分型与乳腺癌新辅助化疗疗效的相关性

Study on relationship between molecular typing and the efficacy of neoadjuvant chemotherapy in breast cancer

目的:探讨乳腺癌分子分型与新辅助化疗疗效的相关性。方法:回顾性分析81例原发乳腺癌患者,分子分型分为HER-2阳性型和三阴型、Luminal A型、Luminal B1型、Luminal B2型,并评估其与乳腺癌新辅助化疗疗效的关系。结果:新辅助化疗疗效与各分子分型之间的相关性无统计学意义,但新辅助化疗有效率达到p CR+tp CR(%)以三阴型最高(25%),其次是HER-2阳性型(23.1%),而达到CR+PR(%)为HER-2阳性型最高(84.6%)。结论:乳腺癌新辅助化疗可有效控制肿瘤,分子分型能作为乳腺癌新辅助化疗疗效的缓解独立预测因子。

Objective：To study the relationship between molecular typing and the efficacy of neoadjuvant chemotherapy in breast cancer.Methods：A retrospective study was conducted in 81 patients with primary breast cancer.Molecular typing is divided into HER-2 positive type and three negative type,Luminal A type,Luminal B1 type,Luminal B2 type,which efficacy with neoadjuvant chemotherapy for breast cancer wes evaluated.Results：There was no significant correlation between the efficacy of neoadjuvant chemotherapy and molecular typing.But in the efficiency of neoadjuvant chemotherapy to pCR＋tpCR（%）,three negative type was highest（25%）,followed by HER-2 positive type（23.1%）,while CR＋PR（%） was the highest in HER-2 positive type（84.6%）.Conclusion：Neoadjuvant chemotherapy for breast cancer can effectively control the tumor.The molecular typing can be used as an independent predictor of neoadjuvant chemotherapy for breast cancer.